Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) had its price objective cut by stock analysts at Chardan Capital from $25.00 to $22.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Chardan Capital also issued estimates for Lexeo Therapeutics' FY2025 earnings at ($3.06) EPS.
A number of other equities analysts also recently commented on LXEO. Royal Bank of Canada reduced their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Finally, Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and an average target price of $22.20.
Check Out Our Latest Stock Analysis on LXEO
Lexeo Therapeutics Stock Performance
Shares of LXEO stock traded down $0.19 on Tuesday, hitting $1.98. The company had a trading volume of 864,163 shares, compared to its average volume of 400,511. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $19.50. The firm has a market cap of $65.73 million, a P/E ratio of -0.63 and a beta of 1.52. The company has a 50-day moving average price of $3.33 and a 200-day moving average price of $5.97. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, equities research analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.
Institutional Trading of Lexeo Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in LXEO. Charles Schwab Investment Management Inc. grew its holdings in shares of Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company's stock worth $577,000 after buying an additional 33,013 shares during the last quarter. BNP Paribas Financial Markets grew its position in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after buying an additional 3,591 shares during the period. MetLife Investment Management LLC increased its stake in Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock valued at $129,000 after purchasing an additional 7,803 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Lexeo Therapeutics during the 3rd quarter worth $274,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Lexeo Therapeutics in the third quarter valued at about $3,348,000. 60.67% of the stock is owned by hedge funds and other institutional investors.
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
See Also
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
